Murayama Masakazu

Research theme for competitive and other funds (1)：

Papers (7)：

Masakazu Murayama, Masahiro Hosonuma, Atsuo Kuramasu, Sei Kobayashi, Akiko Sasaki, Yuta Baba, Yoichiro Narikawa, Hitoshi Toyoda, Junya Isobe, Eiji Funayama, et al. Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody. Scientific reports. 2024. 14. 1. 11325-11325
Masahiro Hosonuma, Yuya Hirasawa, Atsuo Kuramasu, Masakazu Murayama, Yoichiro Narikawa, Hitoshi Toyoda, Yuta Baba, Junya Isobe, Eiji Funayama, Kohei Tajima, et al. Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit. Cancer science. 2024. 115. 3. 752-762
Koji Otsuka, Junya Isobe, Yoshiyuki Asai, Tomohisa Nakano, Kouya Hattori, Tomotake Ariyoshi, Takeshi Yamashita, Kentaro Motegi, Akira Saito, Masahiro Kohmoto, et al. Butyricimonas is a key gut microbiome component for predicting postoperative recurrence of esophageal cancer. Cancer immunology, immunotherapy : CII. 2024. 73. 2. 23-23
Masahiro Hosonuma, Masakazu Murayama, Kiyoshi Yoshimura. [The Gut Microbiota Metabolite A Enhances the Anti-Tumor Effects of Anti-PD-1 Antibody Therapy through Immune Modulation]. Gan to kagaku ryoho. Cancer & chemotherapy. 2023. 50. 9. 960-964
Kazuyuki Hamada, Junya Isobe, Kouya Hattori, Masahiro Hosonuma, Yuta Baba, Masakazu Murayama, Yoichiro Narikawa, Hitoshi Toyoda, Eiji Funayama, Kohei Tajima, et al. Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor. Frontiers in immunology. 2023. 14. 1164724-1164724

ｍore...

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page